tbuckley/cabot-search huggingface dataset:
EXAMINING CONTRIBUTING FACTORS TO ACCURACY OF FETAL ECHOCARDIOGRAPHY IN PRENATAL DIAGNOSIS OF CONGENITAL HEART DISEASE
Authors: Rose He, Kim Haberer, Jayani Abeysekera, Aisling Young, Angela McBrien, Luke Eckersley, Isabella Adatia, Rishav Sharma, Michelle Rushfeldt, Lisa Hornberger
Journal: Journal of the American College of Cardiology (2021)
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
Authors: Naval Daver, Ahmad S. Alotaibi, Veit Bücklein, Marion Subklewe
Journal: Leukemia (2021)

Acute myeloid leukemia (AML) is a heterogeneous disease linked to a broad spectrum of molecular alterations, and as such, long-term disease control requires multiple therapeutic approaches. Driven largely by an improved understanding and targeting of these molecular aberrations, AML treatment has rapidly evolved over the last 3-5 years. The stellar successes of immunotherapies that harness the power of T cells to treat solid tumors and an improved understanding of the immune systems of patients with hematologic malignancies have led to major efforts to develop immunotherapies for the treatment of patients with AML. Several immunotherapies that harness T cells against AML are in various stages of preclinical and clinical development. These include bispecific and dual antigen receptor-targeting antibodies (targeted to CD33, CD123, CLL-1, and others), chimeric antigen receptor (CAR) T-cell therapies, and T-cell immune checkpoint inhibitors (including those targeting PD-1, PD-L1, CTLA-4, and newer targets such as TIM3 and STING). The current and future directions of these T-cell-based immunotherapies in the treatment landscape of AML are discussed in this review.
ROLE AND FUNCTIONAL CHARACTERIZATION OF CUB-DOMAIN CONTAINING PROTEIN 1 (CDCP1) IN DILATED CARDIOMYOPATHY
Authors: Min Wang, Duan Liu, Vishakantha Murthy, Thanh Thanh Nguyen, Do Young Lim, Runqing Huang, Dennis McNamara, Michelle Skime, Anthony Batzler, Gregory Jenkins, Simona Barlera, Silvana Pileggi, Luisa Mestroni, Marco Merlo, Florence Pinet, Pascal de Groote, Jordan Miller, Richard Weinshilboum, Naveen Pereira
Journal: Journal of the American College of Cardiology (2021)
SINUS BRADYCARDIA AS THE INITIAL MANIFESTATION OF COVID-19
Authors: Ivan Mendoza, Karina Gonzalez, Igoor Morr, Yolimar Meza, Radana Bonnemay, Teodardo Marcano, Maria Mateu, Oscar Del Valle, Jose Torres-Viera, Vicente Finizola, Ivan Mendoza
Journal: Journal of the American College of Cardiology (2021)
CARDIOPROTECTIVE EFFECTS OF EZETIMIBE AS AN ADJUNCT TO STATINS VERSUS STATIN UP-TITRATION ON APOLIPOPROTEINS FOR PREVENTION OF ATHEROSCLEROSIS- A SYSTEMATIC REVIEW AND META ANALYSIS
Authors: Aminah Abdul Razzack, Suveenkrishna Pothuru, Chris Andrea Robert, Krishna Teja Challa, Syed Adeel Hassan, Chilsia Safi, Farah Yasmin, Tariq Jamal Siqqui
Journal: Journal of the American College of Cardiology (2021)
ACCELERATED STENOTIC FLOW IN THE LEFT ANTERIOR DESCENDING CORONARY ARTERY DETECTED BY ENHANCED TRANSTHORACIC DOPPLER PREDICTS PLAQUE BURDEN
Authors: Carlo Caiati, Mara Piccolo, Fortunato Iacovelli, Paola Siena, Paolo Pollice, Stefano Favale, Mario Erminio Lepera
Journal: Journal of the American College of Cardiology (2021)
USE OF QUALITY IMPROVEMENT AND SOCIETY OF THORACIC SURGERY INDICATORS IN ADULT CARDIAC SURGERY PROGRAMS IN THE CARIBBEAN
Authors: Nicola Pradegan, Elvis Rivera, Melvin Berroa, Brigida Aguerrevere, Santiago Mena, Octavio Gonzalez, Julius Leiba, Perelló Ricardo, José R. Iribarren, Cesar Herrera
Journal: Journal of the American College of Cardiology (2021)
Lies of Omission and Commission, Providing and Withholding Treatment, Local and Global Autonomy – There Are Reasons for Clinical Ethicists to Attend to All of These Distinctions
Authors: Jonathan Pugh
Journal: The American Journal of Bioethics (2021)

Meyers argues that clinical ethicists should sometimes be active participants in the deception of patients and families, whether that involves lies of omission or commission (Meyers 2021). I shall ...
Skin-Colored Papules on the Right Lower Back of an Elderly Man
Authors: Lu Yang, Yue-Ping Zeng
Journal: JAMA Dermatology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
MITOCHONDRIAL FISSION INHIBITOR AND FUSION PROMOTER IMPROVE LEFT VENTRICULAR FUNCTION IN RATS WITH DOXORUBICIN-INDUCED CARDIOTOXICITY
Authors: Chayodom Maneechote, Thawatchai Khuanjing, Benjamin Ongnok, Apiwan Arinno, Nanthip Prathumsap, Titikorn Chunchai, Busarin Arunsak, Thidarat Jaiwongkam, Sasiwan Kerdphoo, Siriporn Chattipakorn, Nipon Chattipakorn
Journal: Journal of the American College of Cardiology (2021)
HEART RATE INDEX IS ASSOCIATED WITH ADVERSE CLINICAL OUTCOMES IN HEART FAILURE WITH REDUCED EJECTION FRACTION - INSIGHTS FROM THE HF-ACTION TRIAL
Authors: Persey Bediako, Kenneth Bilchick, Kajal Shah, Olivia Blazek, Nishtha Sodhi, Khadijah Breathett, Hunter Mwansa, Nishaki Mehta, Younghoon Kwon, John Hossack, Sula Mazimba
Journal: Journal of the American College of Cardiology (2021)
Deuterium oxide as a contrast medium for real-time MRI-guided endovascular neurointervention
Authors: Lin Chen, Jing Liu, Chengyan Chu, Zheng Han, Nirhbay Yadav, Jiadi Xu, Renyuan Bai, Verena Staedtke, Monica Pearl, Piotr Walczak, Peter van Zijl, Miroslaw Janowski, Guanshu Liu
Journal: Theranostics (2021)

Endovascular intervention plays an important role in the treatment of various diseases, in which MRI-guidance can potentially improve precision. However, the clinical applications of currently available contrast media, including Gadolinium-based contrast agents and superparamagnetic iron oxide particles (SPIO), are hindered by safety concerns. In the present study, we sought to develop D
Correspondence on ‘SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists’
Authors: Gianluca Smerilli, Edoardo Cipolletta, Erica Moscioni, Francesca Francioso, Anna Maria Risa, Vincenzo Maccarrone, Davide Zompa, Andrea Di Matteo, Marco Di Carlo, Rossella De Angelis, Fausto Salaffi, Emilio Filippucci, Walter Grassi
Journal: Annals of the Rheumatic Diseases (2021)

With the significant advances in cancer genomics using next-generation sequencing technologies, genomic and molecular profiling-based precision medicine is used as a part of routine clinical test for guiding and selecting the most appropriate treatments for individual cancer patients. Although many molecular-targeted therapies for a number of actionable genomic alterations have been developed, the clinical application of such information is still limited to a small proportion of cancer patients. In this review, we summarize the current status of personalized drug selection based on genomic and molecular profiling and highlight the challenges how we can further utilize the individual genomic information. Cancer immunotherapies, including immune checkpoint inhibitors, would be one of the potential approaches to apply the results of genomic sequencing most effectively. Highly cancer-specific antigens derived from somatic mutations, the so-called neoantigens, occurring in individual cancers have been in focus recently. Cancer immunotherapies, which target neoantigens, could lead to a precise treatment for cancer patients, despite the challenge in accurately predicting neoantigens that can induce cytotoxic T cells in individual patients. Precise prediction of neoantigens should accelerate the development of personalized immunotherapy including cancer vaccines and T-cell receptor-engineered T-cell therapy for a broader range of cancer patients.
Distribution of pathogens and antimicrobial resistance in bacteraemia according to hospitalization duration: a nationwide surveillance study in Switzerland
Authors: Niccolò Buetti, Jonas Marschall, Jean-François Timsit, Andrew Atkinson, Andreas Kronenberg, Rami Sommerstein, A. Burnens, A. Cherkaoui, C. Corradi, O. Dubuis, A.G. Viollier, A. Egli, V. Gaia, D. Koch, A. Kronenberg, S.L. Leib, J. Marschall, P. Nordmann, V. Perreten, J.-C. Piffaretti, G. Prod'hom, J. Schrenzel, A.F. Widmer, G. Zanetti, R. Zbinden
Journal: Clinical Microbiology and Infection (2021)

ObjectivesChanging microorganism distributions and decreasing antibiotic susceptibility with increasing length of hospital stay have been demonstrated for the colonization or infection of selected organ systems. We wanted to describe microorganism distribution or antibiotic resistance in bacteraemia according to duration of the hospitalization using a large national epidemiological/microbiological database (ANRESIS) in Switzerland.MethodsWe conducted a nationwide, observational study on bacteraemia using ANRESIS data from 1 January 2008 to 31 December 2017. We analysed data on bacteraemia from those Swiss hospitals that sent information on a regular basis during the entire study period. We described the pathogen distribution and specific trends of resistance during hospitalization for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Serratia marcescens and Staphylococcus aureus.ResultsWe included 28 318 bacteraemia isolates from 90 Swiss hospitals. The most common aetiology was E. coli (33.4%, 9459), followed by S. aureus (16.7%, 4721), K. pneumoniae (7.1%, 2005), Enterococcus faecalis (5.2%, 1473), P. aeruginosa (4.3%, 1228), Streptococcus pneumoniae (4.3%, 1208) and Enterococcus faecium (3.9%, 1101). We observed 489 (1.73%) S. marcescens isolates. We observed an increasing trend for E. faecium (from 1.5% at day 0 to 13.7% at day 30; p < 0.001), K. pneumoniae (from 6.1% to 7.8%, p < 0.001) and P. aeruginosa (from 2.9% to 13.7%, p < 0.001) with increasing duration of hospitalization; and decreasing trends for E. coli (from 41.6% to 21.6%; p < 0.001) and S. aureus (p < 0.001). Ceftriaxone resistance among E. coli remained stable for the first 15 days of hospitalization and then increased. Ceftriaxone resistance among K. pneumoniae and S. marcescens and oxacillin resistance among S. aureus increased linearly during the hospitalization. Cefepime resistance among P. aeruginosa remained stable during the hospitalization.DiscussionWe showed that hospitalization duration is associated with a species- and antibiotic class-dependent pattern of antimicrobial resistance.
Heme catabolism by tumor-associated macrophages controls metastasis formation
Authors: Francesca Maria Consonni, Augusto Bleve, Maria Grazia Totaro, Mariangela Storto, Paolo Kunderfranco, Alberto Termanini, Fabio Pasqualini, Chiara Alì, Chiara Pandolfo, Francesco Sgambelluri, Giulia Grazia, Mario Santinami, Andrea Maurichi, Massimo Milione, Marco Erreni, Andrea Doni, Marco Fabbri, Laura Gribaldo, Eliana Rulli, Miguel Parreira Soares, Valter Torri, Roberta Mortarini, Andrea Anichini, Antonio Sica
Journal: Nature Immunology (2021)
OPTIMIZING DAPT DURATION IN PATIENTS WITH 2019 ESC CHRONIC CORONARY SYNDROMES GUIDELINES-ENDORSED MODERATELY ISCHEMIC RISK AFTER CORONARY STENT IMPLANTATION
Authors: Haoyu Wang, Dong Yin, Lei Feng, Chenggang Zhu, Kefei Dou
Journal: Journal of the American College of Cardiology (2021)
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study
Authors: Xinghao Ai, Yueyin Pan, Jianhua Shi, Nong Yang, Chunling Liu, Jianying Zhou, Xiaodong Zhang, Xiaorong Dong, Jianxing He, Xiaoling Li, Gongyan Chen, Xingya Li, Helong Zhang, Wangjun Liao, Yiping Zhang, Zhiyong Ma, Liyan Jiang, Jiuwei Cui, Chunhong Hu, Wei Wang, Cheng Huang, Jun Zhao, Cuimin Ding, Xiaohua Hu, Kai Wang, Beili Gao, Yong Song, Xiaoqing Liu, Jianping Xiong, Anwen Liu, Junling Li, Zhe Liu, Yinyin Li, Mengzhao Wang, Biao Zhang, Dan Zhang, Shun Lu
Journal: Journal of Thoracic Oncology (2021)

IntroductionZL-2306-005 is a randomized, double-blind, multicenter phase 3 study evaluating the efficacy and safety of niraparib, a poly(adenosine diphosphate-ribose) polymerase inhibitor, as first-line maintenance therapy in Chinese patients with platinum-responsive, extensive-stage SCLC (ES-SCLC).MethodsPatients with complete response (CR) or partial response (PR) to standardized, platinum-based first-line chemotherapy were randomized 2:1 to receive niraparib or placebo (300 mg [baseline body weight ≥ 77 kg, platelet count ≥ 150,000/μL] or 200 mg) once daily until progression or unacceptable toxicity. Primary end points were progression-free survival (PFS) (blinded independent central review) and overall survival (sample size planned: 591 patients). Secondary end points included investigator-evaluated PFS and safety.ResultsZL-2306-005 was terminated early owing to ES-SCLC treatment landscape changes (data cutoff: March 20, 2020). During July 2018–February 2020, a total of 185 of 272 patients screened were randomized (niraparib: n = 125 [CR = 1, PR = 124]; placebo: n = 60 [CR = 1, PR = 59]). Median (95% confidence interval [CI]) PFS (blinded independent central review) was 1.54 months (1.41–2.69, niraparib) and 1.36 months (1.31–1.48, placebo); hazard ratio (HR) = 0.66 (95% CI: 0.46–0.95, p = 0.0242). Median overall survival was 9.92 months (9.33–13.54, niraparib) and 11.43 months (9.53–not estimable, placebo); HR = 1.03 (95% CI: 0.62–1.73, p = 0.9052). Median investigator-evaluated PFS was 1.48 months (1.41–2.56, niraparib) and 1.41 months (1.31–2.00, placebo); HR = 0.88 (95% CI: 0.61–1.26; p = 0.4653). Grade greater than or equal to 3 adverse events occurred in 34.4% (niraparib) and 25.0% (placebo) of patients.ConclusionsZL-2306-005 did not reach primary end points. Nevertheless, niraparib as maintenance therapy modestly improved PFS in patients with platinum-responsive ES-SCLC, with acceptable tolerability profile and no new safety signal.
Oral delivery of proteins and peptides: Challenges, status quo and future perspectives
Authors: Quangang Zhu, Zhongjian Chen, Pijush Kumar Paul, Yi Lu, Wei Wu, Jianping Qi
Journal: Acta Pharmaceutica Sinica B (2021)

Proteins and peptides (PPs) have gradually become more attractive therapeutic molecules than small molecular drugs due to their high selectivity and efficacy, but fewer side effects. Owing to the poor stability and limited permeability through gastrointestinal (GI) tract and epithelia, the therapeutic PPs are usually administered by parenteral route. Given the big demand for oral administration in clinical use, a variety of researches focused on developing new technologies to overcome GI barriers of PPs, such as enteric coating, enzyme inhibitors, permeation enhancers, nanoparticles, as well as intestinal microdevices. Some new technologies have been developed under clinical trials and even on the market. This review summarizes the history, the physiological barriers and the overcoming approaches, current clinical and preclinical technologies, and future prospects of oral delivery of PPs.
Evidence in primates supporting the use of chemogenetics for the treatment of human refractory neuropsychiatric disorders
Authors: Patrick H. Roseboom, Sascha A.L. Mueller, Jonathan A. Oler, Andrew S. Fox, Marissa K. Riedel, Victoria R. Elam, Miles E. Olsen, Juan L. Gomez, Matthew A. Boehm, Alexandra H. DiFilippo, Bradley T. Christian, Michael Michaelides, Ned H. Kalin
Journal: Molecular Therapy (2021)

Non-human primate (NHP) models are essential for developing and translating new treatments that target neural circuit dysfunction underlying human psychopathology. As a proof-of-concept for treating neuropsychiatric disorders, we used a NHP model of pathological anxiety to investigate the feasibility of decreasing anxiety by chemogenetically (DREADDs [designer receptors exclusively activated by designer drugs]) reducing amygdala neuronal activity. Intraoperative MRI surgery was used to infect dorsal amygdala neurons with AAV5-hSyn-HA-hM4Di in young rhesus monkeys. In vivo microPET studies with [
Biodegradable metals for bone defect repair: A systematic review and meta-analysis based on animal studies
Authors: Jiazhen Zhang, Yanbiao Jiang, Zhizhong Shang, Bing Zhao, Mingyue Jiao, Wenbo Liu, Maobo Cheng, Bao Zhai, Yajuan Guo, Bin Liu, Xinli Shi, Bin Ma
Journal: Bioactive Materials (2021)

Biodegradable metals are promising candidates for bone defect repair. With an evidence-based approach, this study investigated and analyzed the performance and degradation properties of biodegradable metals in animal models for bone defect repair to explore their potential clinical translation. Animal studies on bone defect repair with biodegradable metals in comparison with other traditional biomaterials were reviewed. Data was carefully collected after identification of population, intervention, comparison, outcome, and study design (PICOS), and following the inclusion criteria of biodegradable metals in animal studies. 30 publications on pure Mg, Mg alloys, pure Zn and Zn alloys were finally included after extraction from a collected database of 2543 publications. A qualitative systematic review and a quantitative meta-analysis were performed. Given the heterogeneity in animal model, anatomical site and critical size defect (CSD), biodegradable metals exhibited mixed effects on bone defect repair and degradation in animal studies in comparison with traditional non-degradable metals, biodegradable polymers, bioceramics, and autogenous bone grafts. The results indicated that there were limitations in the experimental design of the included studies, and quality of the evidence presented by the studies was very low. To enhance clinical translation of biodegradable metals, evidence-based research with data validity is needed. Future studies should adopt standardized experimental protocols in investigating the effects of biodegradable metals on bone defect repair with animal models.
Brain gene co-expression networks link complement signaling with convergent synaptic pathology in schizophrenia
Authors: Minsoo Kim, Jillian R. Haney, Pan Zhang, Leanna M. Hernandez, Lee-kai Wang, Laura Perez-Cano, Loes M. Olde Loohuis, Luis de la Torre-Ubieta, Michael J. Gandal
Journal: Nature Neuroscience (2021)
RECURRENT CARDIOEMBOLIC STROKE IN A PATIENT WITH ATRIAL PALSY SYNDROME
Authors: Hector Lopez de la Garza, Gerardo Emilio Pozas Garza, Jose Gildardo Paredes-Vá zquez, Hector Guillermo Betancourt Del Campo, Jaime Alberto Guajardo Lozano, Diego Ramonfaur, Carlos Jerjes-Sá nchez
Journal: Journal of the American College of Cardiology (2021)
SPONTANEOUS HEMOPERICARDIUM AND TAMPONADE AFTER INITIATION OF ANTICOAGULATION IN A PATIENT WITH ATRIAL FIBRILLATION AND END STAGE RENAL DISEASE; SHOULD WE ANTICOAGULATE PATIENTS ON HEMODIALYSIS?
Authors: Juan Vazquez-Fuster, Jose Escabi-Mendoza
Journal: Journal of the American College of Cardiology (2021)
HEMODYNAMICS ASSOCIATED WITH PRE-PROCEDURAL ELEVATED B-TYPE NATRIURETIC PEPTIDE IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Derek Phan, Jesse Goitia, Ming-Sum Lee, Naing Moore, Prakash Mansukhani, Vicken Aharonian, Somjot Brar, Ray Zadegan
Journal: Journal of the American College of Cardiology (2021)
A CASE OF INCESSANT VENTRICULAR TACHYCARDIA IN A 28-YEAR-OLD WOMAN WITH RHABDOMYOSARCOMA
Authors: Krasimira Mikhova, Geoffrey Orme, Sandeep Sodhi, Phillip Cuculich, Kathleen Zhang, Cliff Robinson, Vladimir N. Despotovic, Angela Hirbe, Marye Gleva
Journal: Journal of the American College of Cardiology (2021)
COMPARISON OF TWO RECENT CERAMIDE-BASED CORONARY RISK PREDICTION SCORES: CERT AND CERT-2
Authors: Andreas Leiherer, Axel Muendlein, Christoph H. Saely, Reijo Laaksonen, Mitja Laaperi, Barbara Larcher, Arthur Mader, Maximilian Maechler, Lukas Sprenger, Beatrix Mutschlechner, Alexander Vonbank, Peter Fraunberger, Heinz Drexel
Journal: Journal of the American College of Cardiology (2021)
Abstract 14876: Predictors of Permanent Pacemaker Insertion After TAVR: A Systematic Review and Meta-Analysis
Authors: Rahul Gupta, Aaqib h Malik, Wilbert S Aronow
Journal: Circulation (2020)

Introduction: Transcatheter Aortic Valve Replacement (TAVR) has evolved as the standard of care for patient with severe aortic stenosis. Conduction abnormalities leading to permanent pacemaker (PPM) implantation is one of the most common complication after TAVR. The aim of this analysis is to evaluate the predictors associated with increased risk of PPM implantation after TAVR. Methods: A comprehensive literature search was performed in PubMed, Embase, and Cochrane to identify relevant trials. Summary effects were calculated using a DerSimonian and Laird random-effects model as odds ratio with 95% confidence intervals for all the clinical endpoints. Results: 37 observational studies with 71455 patients were identified. The incidence of PPM implantation after TAVR in our analysis was 22%. The risk of PPM implantation after TAVR was more in men, it increased with increasing age, and in patients with diabetes mellitus, presence of right bundle branch block , baseline atrioventricular conduction block, and left anterior fascicular block. Significant predictors of PPM insertion post TAVR included the presence of high calcium volume in the area below left and non-coronary cusp, use of self-expandable valve over balloon-expandable valve, depth of implant, valve size/annulus size, pre-dilatation balloon valvuloplasty and post-implant balloon dilation. However, the risk did not increase with atrial fibrillation, left bundle branch block, baseline interventricular conduction delay, change in QRS duration after the procedure and with the presence of high calcium in the area below right coronary cusp. Conclusions: Our meta-analysis identified 14 factors that were significantly associated with increased risk of PPM insertion after TAVR. Early identification of high-risk populations and targeting modifiable risk factors can help to reduce the rate of PPM insertion after TAVR.
EFFECTS OF INCORPORATING LUNG ULTRASOUND IN HEART FAILURE FOLLOW-UP: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Diego Chambergo-Michilot, Astrid Tauma-Arrué, Silvana Loli-Guevara, Mariella R. Huaman, Juan Carlos Mego, Mayita L. Alvarez-Vargas, Pedro A. Segura-Saldaña
Journal: Journal of the American College of Cardiology (2021)